Utah Medical Products (UTMD) EBITDA (2010 - 2026)

Utah Medical Products' EBITDA history runs 17 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, EBITDA fell 18.65% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $10.8 million, a 15.94% decrease from a year earlier, with the FY2025 full-year figure at $11.4 million, down 16.12% from the prior year.
• EBITDA rose to $2.6 million in Q1 2026 per UTMD's latest filing, from $2.4 million in the prior quarter.
• Across five years, EBITDA topped out at $5.1 million in Q3 2022 and bottomed at $2.4 million in Q4 2025.
• The 5-year median for EBITDA is $3.9 million (2024), against an average of $3.8 million.
• Across the five-year window, EBITDA climbed 16.31% in 2022 and dropped 25.71% in 2024, its largest moves.
• Year by year, EBITDA stood at $5.1 million in 2022, then slipped by 22.21% to $3.9 million in 2023, then fell by 25.71% to $2.9 million in 2024, then declined by 16.69% to $2.4 million in 2025, then increased by 5.08% to $2.6 million in 2026.
• Per Business Quant, the three latest UTMD EBITDA figures stand at $2.6 million (Q1 2026), $2.4 million (Q4 2025), and $2.6 million (Q3 2025).